Axicabtagene ciloleucel (Yescarta)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells.

Toxicity management

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient Drug Information

History of changes in FDA indication

History of changes in EMA indication

  • 8/23/2018: Initial marketing authorization as Yescarta.

Also known as

  • Code name: KTE-C19
  • Generic names: Axicel, Axi-cel
  • Brand name: Yescarta

References